Dihydroartemisinin-piperaquine and Primaquine for Uncomplicated Plasmodium Falciparum Cases

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Artemisinin-based combination therapy (ACT) has been known to be controversial for stopping malaria transmission.The addition of primaquine (PQ) - the only drug commercially available that kills mature transmission stage - to such treatments might be necessary to eliminate this stage. A study is conducted to evaluate the efficacy of dihydroartemisinin-piperaquine (DHP) regimens with or without PQ on the sexual and asexual stages of P. falciparum in Sumatra, Indonesia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Indonesia University
• Treatments: Artemisinins; Artenimol; Dihydroartemisinin; Piperaquine; Primaquine

Criteria

Inclusion Criteria:

• age ≥ 4 years old

• parasite count ≥ 1,000 asexual parasites/µL

• normal glucose-6-phosphate dehydrogenase enzyme level based on qualitative test (Trinity Biotech® no 203, USA)

• hemoglobin level ≥ 8 gr/dL as measured by Hemoque® apparatus;

• have the ability to return for 42-day-follow up and

• willingness to sign the informed-consent form.

Exclusion Criteria:

• are infected with other r plasmodium species

• have only gametocytes of P. falciparum;

• are pregnant - measured by positive result on HCG urine test and/or breastfeeding women

• present signs of pitting edema on both legs as a sign of malnutrition

• have complicated or severe malaria, other chronic diseases or history of drug allergies.